FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313497788> ?p ?o ?g. }

• W2313497788 endingPage "817" @default.
• W2313497788 startingPage "809" @default.
• W2313497788 abstract "Adjuvant chemotherapy and neoadjuvant chemotherapy have been widely used as adjuvant treatment in patients requiring total cystectomy for locally advanced transitional cell carcinoma of the bladder. However, there has been no conclusive evidence that the adjunctive chemotherapy improves survival and no agreement exists concerning what subsets of such patients receive significant benefits from the adjunctive chemotherapy. The study retrospectively sought to clarify these points.We retrospectively analyzed clinical and pathological records of the 229 patients with transitional cell carcinoma of the bladder who underwent total cystectomy with or without lymph node dissection in our University Hospital from January 1975 to December 1997. Forty-two patients received 1-4 cycles (mean = 1.7) of adjuvant chemotherapy with VPMisCF (n = 19), CisCA (n = 4), MVAC (n = 8), or MEC (Methotrexate, Epirubicin and Cisplatin) (n = 11). Twenty-three patients received 1-4 cycles (mean = 2.1) of neoadjuvant chemotherapy with CisCA (n = 2), MVAC (n = 5), or MEC (n = 16). Using the Kaplan-Meier method, disease-specific survival rate was assessed according to various clinical and pathological factors as well as the administration of adjuvant or neoadjuvant chemotherapy. The generalized-Wilcoxon test was used to evaluate statistical significance (p < 0.05) of survival curves for two or more groups. In addition, a multivariate analysis using the Cox proportional hazards model was performed with respect to multiple clinical and pathological parameters, and treatment modalities.In patients who received neither adjuvant chemotherapy nor radiotherapy, the disease-specific survival rate was significantly lower in those with pT3a and/or more advanced tumors compared with those with pT2 or less advanced tumors. The survival rate in patients with positive lymph node metastasis was significantly lower than that in patients without lymph node metastasis. No apparent survival benefit was noted for those patients who received adjuvant chemotherapy when compared with patients who had pT3a or more advanced tumor and were followed without any adjunctive therapy. In patients with pN2 or more advanced lymph node metastasis, the survival rate of those who received adjuvant CisCA/MVAC/MEC chemotherapy was significantly higher than that those without any adjunctive therapy. Although no apparent survival benefit was observed in patients who received neoadjuvant chemotherapy, the survival rate in patients whose tumor was considered to be down-staged to pT1 or lower was significantly higher than patients who did not receive neoadjuvant chemotherapy and had pT3a or higher pT-stage tumor. The survival rate in patients whose tumor showed clinical partial or complete response by neoadjuvant chemotherapy was also significantly higher than the same control patients. However, the multivariate analysis revealed no significant survival benefit after adjuvant chemotherapy or after neoadjuvant chemotherapy.Adjuvant chemotherapy after total cystectomy is an acceptable approach in patients with pN2 or higher pN-stage bladder cancer. The significant survival benefit may be obtained who acquired pathological downstaging or partial to complete clinical response after neoadjuvant chemotherapy. To get maximum survival benefit from the present chemotherapeutic regimens and exclude administration of toxic chemotherapeutic agents to unresponsive patients, there should be more reliable markers that give clear information to differentiate tumors that will respond fairly to present chemotherapeutic regimens from tumors that will respond poorly." @default.
• W2313497788 created "2016-06-24" @default.
• W2313497788 creator A5004702538 @default.
• W2313497788 creator A5012066043 @default.
• W2313497788 creator A5016679916 @default.
• W2313497788 creator A5083025134 @default.
• W2313497788 creator A5084772092 @default.
• W2313497788 date "1999-01-01" @default.
• W2313497788 modified "2023-10-16" @default.
• W2313497788 title "THE PROGNOSTIC VALUE OF ADJUVANT AND NEOADJUVANT CHEMOTHERAPY IN TOTAL CYSTECTOMY FOR LOCALLY ADVANCED BLADDER CANCER" @default.
• W2313497788 cites W1426844501 @default.
• W2313497788 cites W1484573141 @default.
• W2313497788 cites W1954311312 @default.
• W2313497788 cites W2004087906 @default.
• W2313497788 cites W2016730689 @default.
• W2313497788 cites W2020419795 @default.
• W2313497788 cites W2051793847 @default.
• W2313497788 cites W2095168415 @default.
• W2313497788 cites W2127066238 @default.
• W2313497788 cites W2130611377 @default.
• W2313497788 cites W2142937757 @default.
• W2313497788 cites W2210089256 @default.
• W2313497788 cites W2398135534 @default.
• W2313497788 cites W2413728555 @default.
• W2313497788 cites W2414280050 @default.
• W2313497788 doi "https://doi.org/10.5980/jpnjurol1989.90.809" @default.
• W2313497788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10565159" @default.
• W2313497788 hasPublicationYear "1999" @default.
• W2313497788 type Work @default.
• W2313497788 sameAs 2313497788 @default.
• W2313497788 citedByCount "0" @default.
• W2313497788 crossrefType "journal-article" @default.
• W2313497788 hasAuthorship W2313497788A5004702538 @default.
• W2313497788 hasAuthorship W2313497788A5012066043 @default.
• W2313497788 hasAuthorship W2313497788A5016679916 @default.
• W2313497788 hasAuthorship W2313497788A5083025134 @default.
• W2313497788 hasAuthorship W2313497788A5084772092 @default.
• W2313497788 hasBestOaLocation W23134977881 @default.
• W2313497788 hasConcept C121608353 @default.
• W2313497788 hasConcept C126322002 @default.
• W2313497788 hasConcept C126894567 @default.
• W2313497788 hasConcept C143998085 @default.
• W2313497788 hasConcept C2775910329 @default.
• W2313497788 hasConcept C2776694085 @default.
• W2313497788 hasConcept C2776755627 @default.
• W2313497788 hasConcept C2778065480 @default.
• W2313497788 hasConcept C2780352672 @default.
• W2313497788 hasConcept C2780835546 @default.
• W2313497788 hasConcept C71924100 @default.
• W2313497788 hasConceptScore W2313497788C121608353 @default.
• W2313497788 hasConceptScore W2313497788C126322002 @default.
• W2313497788 hasConceptScore W2313497788C126894567 @default.
• W2313497788 hasConceptScore W2313497788C143998085 @default.
• W2313497788 hasConceptScore W2313497788C2775910329 @default.
• W2313497788 hasConceptScore W2313497788C2776694085 @default.
• W2313497788 hasConceptScore W2313497788C2776755627 @default.
• W2313497788 hasConceptScore W2313497788C2778065480 @default.
• W2313497788 hasConceptScore W2313497788C2780352672 @default.
• W2313497788 hasConceptScore W2313497788C2780835546 @default.
• W2313497788 hasConceptScore W2313497788C71924100 @default.
• W2313497788 hasIssue "10" @default.
• W2313497788 hasLocation W23134977881 @default.
• W2313497788 hasLocation W23134977882 @default.
• W2313497788 hasOpenAccess W2313497788 @default.
• W2313497788 hasPrimaryLocation W23134977881 @default.
• W2313497788 hasRelatedWork W1572671100 @default.
• W2313497788 hasRelatedWork W1998062456 @default.
• W2313497788 hasRelatedWork W2022837219 @default.
• W2313497788 hasRelatedWork W2066626651 @default.
• W2313497788 hasRelatedWork W2409442590 @default.
• W2313497788 hasRelatedWork W2603025253 @default.
• W2313497788 hasRelatedWork W3032049527 @default.
• W2313497788 hasRelatedWork W3111145153 @default.
• W2313497788 hasRelatedWork W3129080622 @default.
• W2313497788 hasRelatedWork W193346854 @default.
• W2313497788 hasVolume "90" @default.
• W2313497788 isParatext "false" @default.
• W2313497788 isRetracted "false" @default.
• W2313497788 magId "2313497788" @default.
• W2313497788 workType "article" @default.